Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $105.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 98.56% from the company’s previous […]
Related Keywords
, Praxis Precision Medicines Inc , Citigroup Inc , Jefferies Financial Group , Acuta Capital Partners , Connor Clark Lunn Investment Management Ltd , Praxis Precision Medicines , Get Free Report , Financial Group , Precision Medicines , Capital Partners , Lunn Investment Management , Praxis Precision Medicines Daily , Nasdaq Prax , Aprax , Medical , Reiterated Rating , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.